Cenicriviroc

Chemical structure of Cenicriviroc

Cenicriviroc is a pharmaceutical compound that acts as a dual antagonist of the CCR2 and CCR5 receptors. It is primarily being investigated for its potential use in the treatment of non-alcoholic steatohepatitis (NASH) and other inflammatory conditions.

Mechanism of Action

Cenicriviroc functions by blocking the CCR2 and CCR5 receptors, which are involved in the recruitment of monocytes and macrophages to sites of inflammation. By inhibiting these receptors, cenicriviroc reduces the infiltration of inflammatory cells into tissues, thereby potentially alleviating inflammatory conditions such as NASH.

Clinical Development

Cenicriviroc has been evaluated in several clinical trials for its efficacy and safety in treating NASH. The drug has shown promise in reducing liver fibrosis and improving liver function in patients with this condition. It is also being studied for its potential benefits in other diseases characterized by chronic inflammation.

Pharmacokinetics

Cenicriviroc is administered orally and has a favorable pharmacokinetic profile, with good bioavailability and a long half-life that supports once-daily dosing. The drug is metabolized primarily in the liver and excreted in the feces.

Potential Side Effects

As with any medication, cenicriviroc may cause side effects. Commonly reported adverse effects include headache, fatigue, and gastrointestinal disturbances. However, the drug is generally well-tolerated in clinical studies.

Research and Future Directions

Ongoing research is focused on further elucidating the therapeutic potential of cenicriviroc in NASH and other inflammatory diseases. Studies are also exploring its use in combination with other agents to enhance its efficacy and broaden its therapeutic applications.

Related Pages

• CCR2
• CCR5
• Non-alcoholic steatohepatitis
• Inflammation